Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis

Biochemical and Biophysical Research Communications

Volumn 438, Issue 2, 2013, Pages 257-263

  Gonzalez, Julien ^a,b   Mouttalib, Sofia ^a,b   Delage, Christine ^a,b   Calise, Denis ^a,b   Maoret, Jean José ^b,c   Pradère, Jean Philippe ^a,b   Klein, Julie ^a,b   Buffin Meyer, Bénédicte ^a,b   Van der Veen, Betty ^d   Charo, Israel F ^e,f   Heeringa, Peter ^d   Duchene, Johan ^g   Bascands, Jean Loup ^a,b   Schanstra, Joost Peter ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Parc Scientifique de Luminy   (France)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e GLADSTONE INSTITUTE OF CARDIOVASCULAR DISEASE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Fibrosis; Inflammation; Kidney

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; INFLAMMATION; INFLAMMATORY CELL; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUBULAR INTERSTITIAL FIBROSIS;

FIBROSIS; INFLAMMATION; KIDNEY;

ANIMALS; CELL LINE; CHEMOKINE CCL7; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; INFLAMMATION; KIDNEY; KIDNEY TUBULES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

MUS;

EID: 84882637173     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.07.025     Document Type: Article

References (46)

1. Zheng G., Wang Y., Mahajan D., et al. The role of tubulointerstitial inflammation. Kidney Int. Suppl. 2005, S96-100.
2. Bascands J.L., Schanstra J.P. Obstructive nephropathy: insights from genetically engineered animals. Kidney Int. 2005, 68:925-937.
3. Nishida M., Hamaoka K. Macrophage phenotype and renal fibrosis in obstructive nephropathy. Nephron Exp. Nephrol. 2008, 110:e31-36.
4. Klahr S., Morrissey J. Obstructive nephropathy and renal fibrosis. Am. J. Physiol. Renal Physiol. 2002, 283:F861-875.
5. Phanish M.K., Winn S.K., Dockrell M.E. Connective tissue growth factor-(CTGF, CCN2) - a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 2010, 114:e83-92.
6. Grande M.T., Lopez-Novoa J.M. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat. Rev. Nephrol. 2009, 5:319-328.
7. Chevalier R.L., Forbes M.S., Thornhill B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009, 75:1145-1152.
8. Nishida M., Fujinaka H., Matsusaka T., et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J. Clin. Invest. 2002, 110:1859-1868.
9. Nishida M., Okumura Y., Fujimoto S.-I., et al. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem. Biophys. Res. Commun. 2005, 332:11-16.
10. Nishida M., Okumura Y., Ozawa S.-I., et al. MMP-2 inhibition reduces renal macrophage infiltration with increased fibrosis in UUO. Biochem. Biophys. Res. Commun. 2007, 354:133-139.
11. Zhang G., Kim H., Cai X., et al. Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J. Am. Soc. Nephrol. 2003, 14:1234-1253.
12. Sallusto F., Baggiolini M. Chemokines and leukocyte traffic. Nat. Immunol. 2008, 9:949-952.
13. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
14. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998, 338:436-445.
15. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol. Today 1999, 20:254-257.
16. Wada T., Furuichi K., Sakai N., et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 2004, 15:940-948.
17. Chow F.Y., Nikolic-Paterson D.J., Ozols E., et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69:73-80.
18. Schneider A., Panzer U., Zahner G., et al. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-beta. Kidney Int. 1999, 56:135-144.
19. Tsou C.L., Peters W., Si Y., et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest. 2007, 117:902-909.
20. Ong V.H., Evans L.A., Shiwen X., et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum. 2003, 48:1979-1991.
21. Ong V.H., Carulli M.T., Xu S., et al. Cross-talk between MCP-3 and TGFbeta promotes fibroblast collagen biosynthesis. Exp. Cell Res. 2009, 315:151-161.
22. Schenk S., Mal N., Finan A., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007, 25:245-251.
23. Gonzalez J., Klein J., Chauhan S.D., et al. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis. Exp. Biol. Med. (Maywood) 2009, 234:1511-1518.
24. Vielhauer V., Anders H.J., Mack M., et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J. Am. Soc. Nephrol. 2001, 12:1173-1187.
25. Van Damme J., Proost P., Lenaerts J.P., et al. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J. Exp. Med. 1992, 176:59-65.
26. Qi W., Chen X., Poronnik P., et al. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int. J. Biochem. Cell Biol. 2006, 38:1-5.
27. Klein J., Gonzalez J., Duchene J., et al. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J. 2009, 23:134-142.
28. Tan X., He W., Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009, 76:1248-1257.
29. Fragiadaki M., Witherden A.S., Kaneko T., et al. Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo. Matrix Biol. 2011, 30:396-403.
30. Phanish M.K., Wahab N.A., Hendry B.M., et al. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp. Nephrol. 2005, 100:e156-165.
31. Park J., Ryu D.R., Li J.J., et al. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am. J. Physiol. Renal Physiol. 2008, 295:F749-757.
32. Gharaee-Kermani M., Denholm E.M., Phan S.H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem. 1996, 271:17779-17784.
33. Menten P., Wuyts A., Van Damme J. Monocyte chemotactic protein-3. Eur. Cytokine Netw. 2001, 12:554-560.
34. Blanpain C., Migeotte I., Lee B., et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999, 94:1899-1905.
35. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
36. Liu L., Kou P., Zeng Q., et al. CD4+ T Lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis. Am. J. Nephrol. 2012, 36:386-396.
37. Jones M., Cordell J.L., Beyers A.D., et al. Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. J. Immunol. 1993, 150:5429-5435.
38. Kotsianidis I., Nakou E., Bouchliou I., et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2009, 179:1121-1130.
39. Kinsey G.R., Sharma R., Huang L., et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2009, 20:1744-1753.
40. Kinsey G.R., Huang L., Vergis A.L., et al. Regulatory T cells contribute to the protective effect of ischemic preconditioning in the kidney. Kidney Int. 2010, 77:771-780.
41. Lo Re S., Lecocq M., Uwambayinema F., et al. Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis. Am. J. Respir. Crit. Care Med. 2011, 184:1270-1281.
42. Liu F., Liu J., Weng D., et al. CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice. PLoS ONE 2010, 5:e15404.
43. Boveda-Ruiz D., D'Alessandro-Gabazza C.N., Toda M., et al. Differential role of regulatory T cells in early and late stages of pulmonary fibrosis. Immunobiology 2013, 218:245-254.
44. Lutz J., Yao Y., Song E., et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005, 79:655-661.
45. Yu X., Fang Y., Liu H., et al. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol. Dial. Transplant. 2012, 27:3110-3119.
46. Beier J.I., Arteel G.E. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp. Biol. Med. 2012, 237:1-9.